---
title: NSCLC Treatment
---

# NSCLC Treatment

- [[introduction of NSCLC Treatment]] 󰒖
- [[Pathologic stage I to IIIA (N1) of NSCLC Treatment]] 󰒖
- [[Pathologic stage IIIA (N2) to IIIB disease of NSCLC Treatment]] 󰒖
- [[Adeno or Other in Stage IV NSCLC Treatment]] (裡面有重要的 → 表格！)
- Squam
  - [[PD-L1]] ≥50%: Pembrolizumab or chemo/pembro (NEJM 2016;375:1823)
  - PD-L1 <50%: Chemo [carbo/paclitaxel] + pembro (NEJM 2018;379:2040)

> 參考 ➡️ [Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer](https://www.nejm.org/doi/full/10.1056/NEJMoa1810865)

Many are specific tyrosine kinase inhibitors (‘tinibs) directed against EGFR, ALK, etc. [[Amivantamab]] is → an EGFR- MET bispecific mAb. Pembrolizumab is → a mAb against PD-1 on lymphocytes (ie, an immune checkpoint inhibitor).

- from [[non-small cell lung cancers]] 
